https://charts.traderzeitung.de/phases/US6979471090 string(1450) "{"isin":"US6979471090","name":"Palvella Therapeutics Inc","stock_id_xnas":67820195,"stock_id_xnys":null,"generated_at":"2026-09-24 01:34:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":153.53,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":153.85,"close_at":"2026-09-21 23:15:00","complete":true,"perf_pct":0.2084}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":153.34,"close_at":"2026-09-22 11:48:00","complete":true,"perf_pct":-0.3315},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":158.04,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":3.0651},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":149.48,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-5.4164},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Palvella Therapeutics Aktie News & Nachrichten

[WKN: A40RA6 | Symbol: PVLA]

Realtimekurs

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

02.03.2026 um 13 Uhr

Palvella Therapeutics

TOP-5-Kursziele der Analysten am 02.03.26

Palvella Therapeutics [US6979471090] Clear Street besätigt Buy-Rating und erhöht das Kursziel von...

05.12.2025 um 13 Uhr

TOP-5-Kursziele der Analysten am 05.12.25

Rubrik [US7811541090] Baird bekräftigt Buy-Rating und erhöht das Kursziel von 120 auf 130 USD (56...

19.11.2025 um 13 Uhr

TOP-5-Kursziele der Analysten am 19.11.25

Ottobock [DE000BCK2223] Goldman Sachs startet Berichterstattung mit "Buy" und Kursziel 100 Euro (37...

Palvella Therapeutics Nachrichtenticker öffnen

MT Newswires 31.08.2026 14:09 Uhr

Palvella Therapeutics schließt Rolling Submission für NDA von QTORIN Rapamycin ab

08:08 AM EDT, 31.08.2026 (MT Newswires) -- Palvella Therapeutics (PVLA) teilte am Montag mit, dass das Unternehmen die kontinuierliche Einreichung (Ro

MT Newswires 04.08.2026 15:37 Uhr

Palvella Therapeutics verzeichnet größeren Nettoverlust im Q2

09:36 AM EDT, 04.08.2026 (MT Newswires) -- Palvella Therapeutics (PVLA) meldete am Dienstag für das Q2 einen Nettoverlust von 1,52 $ je verwässerter A

MT Newswires 04.08.2026 13:40 Uhr

--Earnings Flash (PVLA) Palvella Therapeutics verzeichnet Q2 Nettoverlust von 1,52 USD je Aktie, verglichen mit FactSet-Schätzung von 1,07 USD Verlust

MT Newswires 22.06.2026 14:27 Uhr